Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment

Sanchis-Artero, Laura; Martínez-Blanch, Juan F.; Manresa-Vera, Sergio; Cortés‐Castell, Ernesto; Valls-Gandia, Marina; Iborra, Marisa; Paredes-Arquiola, Jose Maria; Boscá-Watts, Maia; Huguet, José María; Gil-Borrás, Rafael; Rodriguez-Morales, Josefa; Cortés-Rizo, Xavier

doi:10.1038/s41598-021-88823-2

Cited by 27 publications

(22 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pairwise comparisons between the baseline (week 0) and the endpoint (week 38) showed no significant differences in diversity neither in patients with CD nor in patients with UC (Figure S5). Other studies reported similar results [15,48,49]. To our knowledge, only one study [16] showed a significant increase in alpha diversity post-treatment in 18 patients with severe CD, 88% of whom reached remission.…”

Section: Discussionsupporting

confidence: 68%

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Schierová

Roubalová

Kolář

et al. 2021

Cells

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn’s disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).

show abstract

Section: Discussionsupporting

confidence: 68%

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Schierová

Roubalová

Kolář

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Increased levels of Lachnospira have been associated with successful anti-tumor necrosis factor therapy outcomes in CD patients. 99 , 100 We observed reduced levels of Lachnospira within the Gevers et al 30 dataset, which comprised new onset IBD, and within Lloyd-Price et al, 61 in which we used the first time point from new onset IBD. Thus, Lachnospira may be a potential marker genus for active disease and inflammation.…”

Section: Discussionmentioning

confidence: 93%

Searching for a Consensus Among Inflammatory Bowel Disease Studies: A Systematic Meta-Analysis

Abdel-Rahman

Morgan

2022

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Numerous studies have examined the gut microbial ecology of patients with Crohn’s disease (CD) and ulcerative colitis, but inflammatory bowel disease–associated taxa and ecological effect sizes are not consistent between studies. Methods We systematically searched PubMed and Google Scholar and performed a meta-analysis of 13 studies to analyze how variables such as sample type (stool, biopsy, and lavage) affect results in inflammatory bowel disease gut microbiome studies, using uniform bioinformatic methods for all primary data. Results Reduced alpha diversity was a consistent feature of both CD and ulcerative colitis but was more pronounced in CD. Disease contributed significantly variation in beta diversity in most studies, but effect size varied, and the effect of sample type was greater than the effect of disease. Fusobacterium was the genus most consistently associated with CD, but disease-associated genera were mostly inconsistent between studies. Stool studies had lower heterogeneity than biopsy studies, especially for CD. Conclusions Our results indicate that sample type variation is an important contributor to study variability that should be carefully considered during study design, and stool is likely superior to biopsy for CD studies due to its lower heterogeneity.

show abstract

“…Research indicates that changes in gut microbiota can reliably identify patients with CD responsiveness to TNF therapy, which can improve clinical management, reduce morbidity, and improve symptoms in these patients. Sanchis-Artero et al (77) divided 27 CD patients initiating anti-TNF treatment into responders and nonresponders to evaluate F. prausnitzii/Escherichia coli and F. prausnitzii/C. coccoides ratios before and after 6 months of treatment.…”

Section: Assessment Of Disease Activity and Treatment Efficacymentioning

confidence: 99%

Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease

Guo

Huang

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is characterized by relapse and remission alternately. It remains a great challenge to diagnose and assess disease activity during IBD due to the lack of specific markers. While traditional biomarkers from plasma and stool, such as C-reactive protein (CRP), fecal calprotectin (FC), and S100A12, can be used to measure inflammation, they are not specific to IBD and difficult to determine an effective cut-off value. There is consensus that gut microbiota is crucial for intestinal dysbiosis is closely associated with IBD etiopathology and pathogenesis. Multiple studies have documented differences in the composition of gut microbiota between patients with IBD and healthy individuals, particularly regarding microbial diversity and relative abundance of specific bacteria. Patients with IBD have higher levels of Proteobacteria and lower amounts of Bacteroides, Eubacterium, and Faecalibacterium than healthy individuals. This review summarizes the pros and cons of using traditional and microbiota biomarkers to assess disease severity and treatment outcomes and addresses the possibility of using microbiota-focused interventions during IBD treatment. Understanding the role of microbial biomarkers in the assessment of disease activity and treatment outcomes has the potential to change clinical practice and lead to the development of more personalized therapies.

show abstract

Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment

Cited by 27 publications

References 40 publications

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Searching for a Consensus Among Inflammatory Bowel Disease Studies: A Systematic Meta-Analysis

Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease

Contact Info

Product

Resources

About